Virology & Infectious Diseases RFP Opportunities
Gilead Sciences funds research on HIV prevention and treatment (LEN and BIC/LEN regimens), antifungal therapies, and hepatitis B, C, and D to address scientific gaps and improve patient outcomes.
Funder: Gilead Sciences
Due Dates: January 30, 2026 (INCLUSION Global 2026 LOI) | April 3, 2026 (INCLUSION Global 2026 Full Application) | May 4, 2026 (RESONATE 2026 LOI) | May 29, 2026 (RESONATE 2026 Full Application)
Funding Amounts: INCLUSION Global: Up to $5,000,000 total program; typical award up to $500,000 (larger by discussion). RESONATE: Up to $4,000,000 total program. Award duration: 18–24 months.
Summary: Supports investigator-initiated and collaborative research in HIV prevention and management, antifungal therapies, and hepatitis B, C, and D to address unmet needs and improve patient outcomes.
Key Information: Proposals must align with specific RFP topics and eligibility; see program details below.
Description
Gilead Sciences offers competitive Request for Proposal (RFP) programs to advance research in virology and infectious diseases, with a focus on HIV prevention and management, antifungal therapies, and hepatitis B, C, and D. These RFPs aim to generate high-impact research that informs clinical decision-making and addresses critical gaps in care. The two major 2026 RFPs are:
- INCLUSION Global 2026: Focused on implementation research for twice-yearly Lenacapavir (LEN) for HIV prevention in select countries.
- RESONATE 2026: Supports research to advance HIV treatment outcomes, particularly related to bictegravir/lenacapavir (BIC/LEN) regimens.
Both programs require a Letter of Intent (LOI) as the first step, with selected applicants invited to submit full proposals. Funding is awarded based on scientific merit, relevance, and alignment with program goals.
